Adverse events ( · people with mild/moderate/severe/critical COVID‐19
Levilimab showed no clear difference in adverse events ( compared with standard care/placebo (low certainty).
1 finding from 1 review
Adverse events ( · people with mild/moderate/severe/critical COVID‐19
Tociliuzumab showed no clear difference in adverse events ( compared with standard care/placebo (moderate certainty).
1 finding from 1 review
Adverse events ( · individuals with moderate or severe COVID‐19
1 finding from 1 review
Adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA probably leads to lower adverse events compared with SASP (moderate certainty).
1 finding from 1 review
Adverse events · Patients with active mild to moderate ulcerative colitis
Once daily dosing showed no clear difference in adverse events compared with conventional dosing (moderate certainty).
1 finding from 1 review
Adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA showed no clear difference in adverse events compared with comparator 5‐ASA (moderate certainty).
1 finding from 1 review
Adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA showed no clear difference in adverse events compared with placebo (high certainty).
1 finding from 1 review
Adverse events · people with moderate to severe Crohn's disease in remission
Briakinumab showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
Adverse events · people with moderate to severe Crohn's disease in remission
Ustekinumab showed no clear difference in adverse events compared with placebo (high certainty).
1 finding from 1 review
Adverse events · children with hypoglycaemia associated with moderate clinical symptoms of acute malaria or moderate respiratory tract infections
1 finding from 1 review
Adverse events · Apathy in people with mild‐to‐moderate Alzheimer's disease
Methylphenidate showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events · People with asthma (mostly mild or moderate)
1 finding from 1 review
Adverse events · Children and adolescents below 18 years at study start (included studies: children from birth to 15 years), with mixed, permanent or…
1 finding from 1 review
Adverse events · Patients with moderately to severely active ulcerative colitis
Vedolizumab showed no clear difference in adverse events compared with placebo (high certainty).
1 finding from 1 review
Adverse events · Patients with pain after surgical removal of lower wisdom teeth (third molars) requiring bone removal or with baseline moderate to severe…
1 finding from 1 review
The majority of adverse events were minor in nature and usually included nausea, vomiting, headaches and dizziness. Side effect profiles have not been included in a meta-analysis as multiple adverse events were…
2 studies
GRADE not reported
Adverse events · Patients with pain after surgical removal of lower wisdom teeth (third molars) requiring bone removal or with baseline moderate to severe…
1 finding from 1 review
The majority of adverse events were minor in nature and usually included nausea, vomiting, headaches and dizziness. Side effect profiles have not been included in a meta-analysis as multiple adverse events were…
7 studies
GRADE not reported
Adverse events · patients with vomiting related to acute gastroenteritis with mild to moderate dehydration
1 finding from 1 review
Local adverse events: skin thinning; end of treatment (1 to 3 weeks) · children and adults, most with moderate to severe eczema
1 finding from 1 review
Systemic adverse events: abnormal cortisol; end of treatment (1‐6 weeks) · children and adults, most with moderate to severe eczema
1 finding from 1 review
Any adverse events · Apathy in people with mild‐to‐moderate Alzheimer's disease
Souvenaid showed no clear difference in any adverse events compared with placebo (moderate certainty).
1 finding from 1 review